TGFBR2 KD mutants do not phosphorylate TGFBR1

Stable Identifier
R-HSA-3645780
Type
Reaction [transition]
Species
Homo sapiens
Compartment
cytosol, plasma membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
TGFBR2 KD mutants do not phosphorylate TGFBR1
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
Phosphorylation of TGFBR1 by TGFBR2 kinase domain (KD) mutants has not been directly experimentally examined. Residues targeted by missense mutations that were shown to impair TGF-beta (TGFB1)-mediated signaling - arginine R528, aspartic acid D522, glutamic acid E526, tyrosine Y470 (Grady et al. 1999, Tanaka et al. 2000) - are conserved between human, mouse, rat, chicken, zebrafish and Xenopus TGFBR2. These residues, especially R528, are also conserved or partially conserved in other serine/threonine kinases (Lin et al. 1992), which is indicative of their importance for the catalytic activity of TGFBR2. Therefore, TGFBR2 KD mutants TGFBR2 R528H, TGFBR2 R528H, TGFBR2 D522N, TGFBR2 Y470D and TGFBR2 E526Q are likely catalytically inactive and unable to phosphorylate and activate TGFBR1.

Presentation of TGFBR2 kinase domain (KD) mutants on the cell surface and their interaction with TGF-beta (TGFB1) and subsequently TGFBR1 has not been directly experimentally examined. However, as mutations affecting the kinase domain in TGFBR2 are missense mutations of conserved residues in the kinase domain, while the rest of the TGFBR2 sequence is intact (Grady et al. 1999, Tanaka et al. 2000), TGFBR2 KD mutants are expected to behave similarly to the wild-type TGFBR2 with respect to cell surface expression, ligand binding, and TGFBR1 interaction.
Literature References
PubMed ID Title Journal Year
10789724 A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma

Tanaka, S, Mori, M, Mafune, K, Ohno, S, Sugimachi, K

Br. J. Cancer 2000
9927040 Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers

Grady, WM, Myeroff, L, Swinler, SE, Rajput, A, Thiagalingam, S, Lutterbaugh, JD, Neumann, A, Brattain, MG, Chang, J, Kim, SJ, Kinzler, KW, Vogelstein, B, Willson, JK, Markowitz, S

Cancer Res. 1999
1310899 Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase

Lin, HY, Wang, XF, Ng-Eaton, E, Weinberg, RA, Lodish, HF

Cell 1992
Participants
Input
Participates
as an event of
Normal reaction
TGFBR2 phosphorylates TGFBR1 (Homo sapiens)
Functional status

Loss of function of TGFB1:TGFBR2 KD Mutants:TGFBR1 [plasma membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Mondo
Authored
Meyer, S  (2013-08-08)
Akhurst, RJ  (2013-08-08)
Orlic-Milacic, M  (2013-08-08)
Reviewed
Meyer, S  (2013-08-08)
Akhurst, RJ  (2013-08-08)
Created
Orlic-Milacic, M  (2013-05-30)
Cite Us!